Clemastine Treatment in Individuals With Williams Syndrome
Williams Syndrome
About this trial
This is an interventional treatment trial for Williams Syndrome focused on measuring Clemastine, Cognition, Myelination abnormalities
Eligibility Criteria
Inclusion Criteria: Individuals with Williams syndrome, which has been confirmed by genetic testing. Ages 6-30. Normal values in safety variables (e.g. Normal ECG 120-129/80-84). No change in psychotropic medications and dosage during the last 4 weeks. During the study, no pharmacological change that may impact the study (e.g. ADHD medications). Exclusion Criteria: Individuals with another genetic disorder besides Williams syndrome. Individuals with Williams syndrome, younger than 6 or older than 30 years old. Significant change in normal values in safety variables (e.g. high or low ECG). Change in medications and dosage during the last 4 weeks prior the beginning and during the study. Pregnancy. Using addictive substances such as alcohol.
Sites / Locations
- Child and Adolescent Psychiatry Unit, Sheba Medical CenterRecruiting
- Tel Aviv UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Open Label
Blinded randomize withdrawal